{"id":341537,"date":"2025-08-20T15:11:45","date_gmt":"2025-08-20T15:11:45","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-editas-medicine\/"},"modified":"2025-08-20T15:11:45","modified_gmt":"2025-08-20T15:11:45","slug":"how-to-buy-editas-medicine","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/","title":{"rendered":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Editas Medicine (EDIT) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $2.63, 6 ayl\u0131k performans analizi ve 2025-2030 i\u00e7in uzman tahminleri. Stratejik giri\u015f noktalar\u0131n\u0131 ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Editas Medicine (EDIT) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat $2.63, 6 ayl\u0131k performans analizi ve 2025-2030 i\u00e7in uzman tahminleri. Stratejik giri\u015f noktalar\u0131n\u0131 ke\u015ffedin."},"intro":"Gen d\u00fczenleme alan\u0131nda yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Editas Medicine (EDIT), biyoteknoloji d\u00fcnyas\u0131nda bug\u00fcn en heyecan verici f\u0131rsatlardan biridir. Bu \u015firket, genetik hastal\u0131klar\u0131n tedavisinde devrim yaratma potansiyeline sahip CRISPR teknolojisinin \u00f6n saflar\u0131nda yer almaktad\u0131r. Mevcut hisse performans\u0131ndan stratejik giri\u015f noktalar\u0131na kadar her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z\u2014t\u0131p gelece\u011fini ke\u015ffetmeye haz\u0131r yeni yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel.","intro_source":{"label":"Intro","type":"text","formatted_value":"Gen d\u00fczenleme alan\u0131nda yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Editas Medicine (EDIT), biyoteknoloji d\u00fcnyas\u0131nda bug\u00fcn en heyecan verici f\u0131rsatlardan biridir. Bu \u015firket, genetik hastal\u0131klar\u0131n tedavisinde devrim yaratma potansiyeline sahip CRISPR teknolojisinin \u00f6n saflar\u0131nda yer almaktad\u0131r. Mevcut hisse performans\u0131ndan stratejik giri\u015f noktalar\u0131na kadar her \u015feyi a\u00e7\u0131klayaca\u011f\u0131z\u2014t\u0131p gelece\u011fini ke\u015ffetmeye haz\u0131r yeni yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel."},"body_html":"<h2>\ud83d\udcc8 Editas Medicine Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla Editas Medicine (EDIT) <strong>$2.63<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014Nisan ay\u0131 diplerinden ola\u011fan\u00fcst\u00fc bir toparlanma hikayesi. Ancak takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> kesinlikle kritik. Editas o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar b\u00fcy\u00fck fiyat hareketlerine neden oluyor.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 EDIT Hissesini Nas\u0131l Hareket Ettirir<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>12 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>$2.50<\/td><td>%3.15 art\u0131\u015f (ilk y\u00fckseli\u015f)<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>$1.20<\/td><td>%15 art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>\u015eubat 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>$0.95<\/td><td>%8 art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>Ortakl\u0131k Haberi<\/td><td>$1.10<\/td><td>%12 art\u0131\u015f (BMS i\u015fbirli\u011fi)<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>Klinik Veri<\/td><td>$1.30<\/td><td>%5 d\u00fc\u015f\u00fc\u015f (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Bilgisi<\/strong>: Pozitif klinik g\u00fcncellemeler ve ortakl\u0131k haberleri genellikle %10-15 kazan\u00e7 sa\u011flarken, kazan\u00e7 ka\u00e7\u0131rmalar\u0131 ge\u00e7ici %5-8 d\u00fc\u015f\u00fc\u015flere yol a\u00e7ar. Hisse, aksiliklerden h\u0131zl\u0131ca toparlanarak ola\u011fan\u00fcst\u00fc dayan\u0131kl\u0131l\u0131k g\u00f6sterdi.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Krizden Geri D\u00f6n\u00fc\u015fe<\/h2> <p>Editas hisseleri Nisan 2025'ten bu yana inan\u0131lmaz bir <strong>%180+ getiri<\/strong> sa\u011flad\u0131:<\/p> <ul> <li><strong>\u015eubat<\/strong>: $0.95 (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Nisan<\/strong>: $0.91 (52 haftal\u0131k dip, piyasa k\u00f6t\u00fcmserli\u011fi zirvesi)<\/li> <li><strong>Haziran<\/strong>: $2.10 (pozitif verilerle toparlanma ba\u015flad\u0131)<\/li> <li><strong>A\u011fustos<\/strong>: $2.63 (mevcut seviye, s\u00fcrd\u00fcr\u00fclen momentum)<\/li> <\/ul> <p>Dramatik d\u00f6n\u00fc\u015f\u00fcn sebebi nedir?<\/p> <ul> <li>In vivo d\u00fczenleme i\u00e7in ba\u015far\u0131l\u0131 preklinik veriler<\/li> <li>Stratejik olarak sadece in vivo yakla\u015f\u0131mlara odaklanma<\/li> <li>Q2 2027'ye kadar uzayan g\u00fc\u00e7l\u00fc nakit pozisyonu<\/li> <li>Bristol Myers Squibb ortakl\u0131k kilometre ta\u015flar\u0131<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: $3.50-4.00 (3. \u00e7eyrek kazan\u00e7 kataliz\u00f6r\u00fc + aday se\u00e7imi) \u2192 <strong>AL<\/strong><\/li> <li><strong>2026<\/strong>: $4.50-6.00 (IND dosyalama ba\u015far\u0131s\u0131 + klinik ilerleme)<\/li> <li><strong>2028<\/strong>: $8.00-12.00 (potansiyel Faz 2 veri a\u00e7\u0131klamalar\u0131)<\/li> <li><strong>2030<\/strong>: $15.00+ (ilk ticari onaylar m\u00fcmk\u00fcn)<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: Y\u00fcksek risk, y\u00fcksek \u00f6d\u00fcll\u00fc f\u0131rsat. \u00c7e\u015fitlendirilmi\u015f portf\u00f6yde <strong>spek\u00fclatif tahsis<\/strong> i\u00e7in ideal.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: Biyoteknoloji ila\u00e7lar\u0131n\u0131n %90'\u0131 denemelerde ba\u015far\u0131s\u0131z olur<\/li> <li><strong>Reg\u00fclasyon engelleri<\/strong>: FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemezdir<\/li> <li><strong>Nakit t\u00fcketimi<\/strong>: $178.5M nakde ra\u011fmen Ar-Ge maliyetleri y\u00fcksek<\/li> <li><strong>Rekabet<\/strong>: CRISPR Therapeutics ve Intellia yak\u0131n rakipler<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Gelir patlamas\u0131<\/strong>: 2. \u00e7eyrekte %597 Y\u0131ll\u0131k B\u00fcy\u00fcme (<a href=\"https:\/\/www.ainvest.com\/news\/editas-medicine-2025-q2-earnings-narrows-losses-revenue-surge-2508\/\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>)<\/li> <li><strong>B\u00fcy\u00fck kilometre ta\u015f\u0131<\/strong>: CD19 program\u0131 i\u00e7in IND kabul\u00fc Bristol Myers \u00f6demesini tetikledi<\/li> <li><strong>Sekt\u00f6r r\u00fczgarlar\u0131<\/strong>: Gen d\u00fczenleme pazar\u0131 y\u0131ll\u0131k %20 b\u00fcy\u00fcme bekleniyor<\/li> <li><strong>Nakit runway<\/strong>: Operasyonlar Q2 2027'ye kadar finanse edildi (<a href=\"https:\/\/www.nasdaq.com\/articles\/why-editas-medicine-stock-was-skyrocketing-week\">Nasdaq Analizi<\/a>)<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 EDIT'e ay\u0131rmay\u0131n\u2014bu spek\u00fclatif biyoteknoloji<\/li> <li><strong>Giri\u015f i\u00e7in bekleyin<\/strong>: 3 Kas\u0131m'daki 3. \u00e7eyrek kazan\u00e7lar\u0131ndan sonra bir d\u00fc\u015f\u00fc\u015f olursa almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Stop-loss koyun<\/strong>: Volatilite nedeniyle %20-25 stop-loss ile kendinizi koruyun<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Gen d\u00fczenleme 5-10 y\u0131ll\u0131k bir hikayedir, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li> <\/ol> <p>Esprili yorum: \"EDIT ticareti yapmak gen cerrahisi yapmak gibidir\u2014sakin eller ve sab\u0131r gerekir. Bir yanl\u0131\u015f hamle yaparsan\u0131z portf\u00f6y\u00fcn\u00fcz\u00fc onarmak i\u00e7in finansal CRISPR gerekebilir!\"<\/p> <h2>\u2705 Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ hisseleri ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Stratejinizi test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"EDIT\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014%1'in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><td>$2.50 destek ve $3.00 diren\u00e7 gibi \u00f6nemli seviyeleri takip edin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>K\u00e2r alma ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <tr><td>8<\/td><td>Tezinizi belgeleyin<\/td><td>Duygusal kararlar almamak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td><\/tr> <tr><td>9<\/td><td>Haber ak\u0131\u015f\u0131n\u0131 takip edin<\/td><td>\"Editas Medicine\" ve \"CRISPR\" i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>10<\/td><td>\u00dc\u00e7 ayl\u0131k olarak g\u00f6zden ge\u00e7irin<\/td><td>Her kazan\u00e7 raporundan sonra pozisyonunuzu yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde de\u011fi\u015ftiriyor:<\/p> <ul> <li><strong>Minimum depozito sadece $5<\/strong>\u2014biyoteknoloji stratejilerini risksiz test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong>: Herhangi bir kimlik belgesini y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong>: Kripto para, e-c\u00fczdanlar ve geleneksel banka transferleri dahil<\/li> <li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>: Pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc karma\u015f\u0131k biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131larken, geli\u015fmi\u015f grafik ara\u00e7lar\u0131 EDIT'in volatil hareketlerini takip etmenize yard\u0131mc\u0131 olur.<\/p> <h2>\ud83c\udf0d 2025'te Editas Medicine: CRISPR \u00d6nc\u00fcs\u00fc<\/h2> <p>Editas Medicine, gen d\u00fczenleme devriminin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket stratejik olarak sadece <strong>in vivo gen d\u00fczenlemeye<\/strong> odaklanmaya y\u00f6neldi\u2014hastal\u0131klar\u0131, h\u00fccreleri \u00e7\u0131karmak yerine do\u011frudan v\u00fccut i\u00e7inde genleri d\u00fczenleyerek tedavi etmek.<\/p> <p><strong>Mevcut Piyasa Konumu<\/strong>: Yakla\u015f\u0131k 270 milyon dolar piyasa de\u011feri ile Editas, b\u00fcy\u00fck potansiyele sahip mikro kapl\u0131 bir biyoteknoloji \u015firketi olarak faaliyet g\u00f6steriyor. Bristol Myers Squibb ile CD19 CAR-T terapisi \u00fczerine i\u015fbirli\u011fi, teknolojilerinin \u00f6nemli bir do\u011frulamas\u0131n\u0131 temsil ediyor.<\/p> <p><strong>2025 At\u0131l\u0131m\u0131<\/strong>: Editas, hedeflenmi\u015f lipid nanopartik\u00fcller kullanarak <strong>insan d\u0131\u015f\u0131 primatlarda in vivo HBG1\/2 promot\u00f6r d\u00fczenlemesini<\/strong> ba\u015far\u0131yla g\u00f6sterdi\u2014kans\u0131z hastal\u0131klar ve beta talasemi tedavisinde invaziv prosed\u00fcrlere gerek kalmadan \u00f6nemli bir ad\u0131m.<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025'te Editas bilim insanlar\u0131, lipid nanopartik\u00fcl ta\u015f\u0131ma sistemlerinin CRISPR teknolojisiyle daha \u00f6nce m\u00fcmk\u00fcn olmad\u0131\u011f\u0131 d\u00fc\u015f\u00fcn\u00fclen \u015fekilde birden fazla doku tipinde gen d\u00fczenleyebilece\u011fini ke\u015ffettiler. Bu \"tak ve \u00e7al\u0131\u015ft\u0131r\" yetene\u011fi genetik t\u0131pta yakla\u015f\u0131m\u0131m\u0131z\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Editas Medicine Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla Editas Medicine (EDIT) <strong>$2.63<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014Nisan ay\u0131 diplerinden ola\u011fan\u00fcst\u00fc bir toparlanma hikayesi. Ancak takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> kesinlikle kritik. Editas o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar b\u00fcy\u00fck fiyat hareketlerine neden oluyor.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 EDIT Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>12 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$2.50<\/td>\n<td>%3.15 art\u0131\u015f (ilk y\u00fckseli\u015f)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$1.20<\/td>\n<td>%15 art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>\u015eubat 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>$0.95<\/td>\n<td>%8 art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>$1.10<\/td>\n<td>%12 art\u0131\u015f (BMS i\u015fbirli\u011fi)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>Klinik Veri<\/td>\n<td>$1.30<\/td>\n<td>%5 d\u00fc\u015f\u00fc\u015f (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Bilgisi<\/strong>: Pozitif klinik g\u00fcncellemeler ve ortakl\u0131k haberleri genellikle %10-15 kazan\u00e7 sa\u011flarken, kazan\u00e7 ka\u00e7\u0131rmalar\u0131 ge\u00e7ici %5-8 d\u00fc\u015f\u00fc\u015flere yol a\u00e7ar. Hisse, aksiliklerden h\u0131zl\u0131ca toparlanarak ola\u011fan\u00fcst\u00fc dayan\u0131kl\u0131l\u0131k g\u00f6sterdi.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Krizden Geri D\u00f6n\u00fc\u015fe<\/h2>\n<p>Editas hisseleri Nisan 2025&#8217;ten bu yana inan\u0131lmaz bir <strong>%180+ getiri<\/strong> sa\u011flad\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: $0.95 (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Nisan<\/strong>: $0.91 (52 haftal\u0131k dip, piyasa k\u00f6t\u00fcmserli\u011fi zirvesi)<\/li>\n<li><strong>Haziran<\/strong>: $2.10 (pozitif verilerle toparlanma ba\u015flad\u0131)<\/li>\n<li><strong>A\u011fustos<\/strong>: $2.63 (mevcut seviye, s\u00fcrd\u00fcr\u00fclen momentum)<\/li>\n<\/ul>\n<p>Dramatik d\u00f6n\u00fc\u015f\u00fcn sebebi nedir?<\/p>\n<ul>\n<li>In vivo d\u00fczenleme i\u00e7in ba\u015far\u0131l\u0131 preklinik veriler<\/li>\n<li>Stratejik olarak sadece in vivo yakla\u015f\u0131mlara odaklanma<\/li>\n<li>Q2 2027&#8217;ye kadar uzayan g\u00fc\u00e7l\u00fc nakit pozisyonu<\/li>\n<li>Bristol Myers Squibb ortakl\u0131k kilometre ta\u015flar\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: $3.50-4.00 (3. \u00e7eyrek kazan\u00e7 kataliz\u00f6r\u00fc + aday se\u00e7imi) \u2192 <strong>AL<\/strong><\/li>\n<li><strong>2026<\/strong>: $4.50-6.00 (IND dosyalama ba\u015far\u0131s\u0131 + klinik ilerleme)<\/li>\n<li><strong>2028<\/strong>: $8.00-12.00 (potansiyel Faz 2 veri a\u00e7\u0131klamalar\u0131)<\/li>\n<li><strong>2030<\/strong>: $15.00+ (ilk ticari onaylar m\u00fcmk\u00fcn)<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: Y\u00fcksek risk, y\u00fcksek \u00f6d\u00fcll\u00fc f\u0131rsat. \u00c7e\u015fitlendirilmi\u015f portf\u00f6yde <strong>spek\u00fclatif tahsis<\/strong> i\u00e7in ideal.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: Biyoteknoloji ila\u00e7lar\u0131n\u0131n %90&#8217;\u0131 denemelerde ba\u015far\u0131s\u0131z olur<\/li>\n<li><strong>Reg\u00fclasyon engelleri<\/strong>: FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemezdir<\/li>\n<li><strong>Nakit t\u00fcketimi<\/strong>: $178.5M nakde ra\u011fmen Ar-Ge maliyetleri y\u00fcksek<\/li>\n<li><strong>Rekabet<\/strong>: CRISPR Therapeutics ve Intellia yak\u0131n rakipler<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Gelir patlamas\u0131<\/strong>: 2. \u00e7eyrekte %597 Y\u0131ll\u0131k B\u00fcy\u00fcme (<a href=\"https:\/\/www.ainvest.com\/news\/editas-medicine-2025-q2-earnings-narrows-losses-revenue-surge-2508\/\">2. \u00c7eyrek Kazan\u00e7 Raporu<\/a>)<\/li>\n<li><strong>B\u00fcy\u00fck kilometre ta\u015f\u0131<\/strong>: CD19 program\u0131 i\u00e7in IND kabul\u00fc Bristol Myers \u00f6demesini tetikledi<\/li>\n<li><strong>Sekt\u00f6r r\u00fczgarlar\u0131<\/strong>: Gen d\u00fczenleme pazar\u0131 y\u0131ll\u0131k %20 b\u00fcy\u00fcme bekleniyor<\/li>\n<li><strong>Nakit runway<\/strong>: Operasyonlar Q2 2027&#8217;ye kadar finanse edildi (<a href=\"https:\/\/www.nasdaq.com\/articles\/why-editas-medicine-stock-was-skyrocketing-week\">Nasdaq Analizi<\/a>)<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 EDIT&#8217;e ay\u0131rmay\u0131n\u2014bu spek\u00fclatif biyoteknoloji<\/li>\n<li><strong>Giri\u015f i\u00e7in bekleyin<\/strong>: 3 Kas\u0131m&#8217;daki 3. \u00e7eyrek kazan\u00e7lar\u0131ndan sonra bir d\u00fc\u015f\u00fc\u015f olursa almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Stop-loss koyun<\/strong>: Volatilite nedeniyle %20-25 stop-loss ile kendinizi koruyun<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Gen d\u00fczenleme 5-10 y\u0131ll\u0131k bir hikayedir, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li>\n<\/ol>\n<p>Esprili yorum: &#8220;EDIT ticareti yapmak gen cerrahisi yapmak gibidir\u2014sakin eller ve sab\u0131r gerekir. Bir yanl\u0131\u015f hamle yaparsan\u0131z portf\u00f6y\u00fcn\u00fcz\u00fc onarmak i\u00e7in finansal CRISPR gerekebilir!&#8221;<\/p>\n<h2>\u2705 Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ hisseleri ve par\u00e7al\u0131 hisse sunan bir platform oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Stratejinizi test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;EDIT&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014%1&#8217;in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<td>$2.50 destek ve $3.00 diren\u00e7 gibi \u00f6nemli seviyeleri takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>K\u00e2r alma ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Tezinizi belgeleyin<\/td>\n<td>Duygusal kararlar almamak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Haber ak\u0131\u015f\u0131n\u0131 takip edin<\/td>\n<td>&#8220;Editas Medicine&#8221; ve &#8220;CRISPR&#8221; i\u00e7in Google uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00dc\u00e7 ayl\u0131k olarak g\u00f6zden ge\u00e7irin<\/td>\n<td>Her kazan\u00e7 raporundan sonra pozisyonunuzu yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde de\u011fi\u015ftiriyor:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece $5<\/strong>\u2014biyoteknoloji stratejilerini risksiz test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong>: Herhangi bir kimlik belgesini y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong>: Kripto para, e-c\u00fczdanlar ve geleneksel banka transferleri dahil<\/li>\n<li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>: Pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc karma\u015f\u0131k biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131larken, geli\u015fmi\u015f grafik ara\u00e7lar\u0131 EDIT&#8217;in volatil hareketlerini takip etmenize yard\u0131mc\u0131 olur.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Editas Medicine: CRISPR \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Editas Medicine, gen d\u00fczenleme devriminin \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirket stratejik olarak sadece <strong>in vivo gen d\u00fczenlemeye<\/strong> odaklanmaya y\u00f6neldi\u2014hastal\u0131klar\u0131, h\u00fccreleri \u00e7\u0131karmak yerine do\u011frudan v\u00fccut i\u00e7inde genleri d\u00fczenleyerek tedavi etmek.<\/p>\n<p><strong>Mevcut Piyasa Konumu<\/strong>: Yakla\u015f\u0131k 270 milyon dolar piyasa de\u011feri ile Editas, b\u00fcy\u00fck potansiyele sahip mikro kapl\u0131 bir biyoteknoloji \u015firketi olarak faaliyet g\u00f6steriyor. Bristol Myers Squibb ile CD19 CAR-T terapisi \u00fczerine i\u015fbirli\u011fi, teknolojilerinin \u00f6nemli bir do\u011frulamas\u0131n\u0131 temsil ediyor.<\/p>\n<p><strong>2025 At\u0131l\u0131m\u0131<\/strong>: Editas, hedeflenmi\u015f lipid nanopartik\u00fcller kullanarak <strong>insan d\u0131\u015f\u0131 primatlarda in vivo HBG1\/2 promot\u00f6r d\u00fczenlemesini<\/strong> ba\u015far\u0131yla g\u00f6sterdi\u2014kans\u0131z hastal\u0131klar ve beta talasemi tedavisinde invaziv prosed\u00fcrlere gerek kalmadan \u00f6nemli bir ad\u0131m.<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025&#8217;te Editas bilim insanlar\u0131, lipid nanopartik\u00fcl ta\u015f\u0131ma sistemlerinin CRISPR teknolojisiyle daha \u00f6nce m\u00fcmk\u00fcn olmad\u0131\u011f\u0131 d\u00fc\u015f\u00fcn\u00fclen \u015fekilde birden fazla doku tipinde gen d\u00fczenleyebilece\u011fini ke\u015ffettiler. Bu &#8220;tak ve \u00e7al\u0131\u015ft\u0131r&#8221; yetene\u011fi genetik t\u0131pta yakla\u015f\u0131m\u0131m\u0131z\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir!<\/p>\n"},"faq":[{"question":"Editas Medicine hisseleri nereden al\u0131n\u0131r?","answer":"Editas Medicine hisseleri NASDAQ borsas\u0131nda \"EDIT\" sembol\u00fc ile i\u015flem g\u00f6r\u00fcr. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Editas Medicine hissesi almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r. Baz\u0131 platformlar par\u00e7al\u0131 hisse al\u0131m\u0131na izin vererek d\u00fc\u015f\u00fck miktarlarla yat\u0131r\u0131m yapman\u0131za olanak tan\u0131r."},{"question":"Editas Medicine hissesi almak riskli midir?","answer":"Evet, biyoteknoloji hisseleri genellikle y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak fiyatlar\u0131 b\u00fcy\u00fck dalgalanmalar g\u00f6sterebilir."},{"question":"Editas Medicine hissesi i\u00e7in uzun vadeli beklentiler nelerdir?","answer":"Uzmanlar, 2025-2030 aras\u0131nda \u015firketin \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip oldu\u011funu ve gen d\u00fczenleme alan\u0131nda \u00f6nc\u00fc konumunu g\u00fc\u00e7lendirece\u011fini \u00f6ng\u00f6rmektedir."},{"question":"Editas Medicine hissesi al\u0131rken nelere dikkat etmeliyim?","answer":"Piyasa haberlerini takip etmek, kazan\u00e7 raporlar\u0131n\u0131 incelemek, stop-loss kullanmak ve portf\u00f6y\u00fcn\u00fczde spek\u00fclatif bir pay ay\u0131rmak \u00f6nemlidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Editas Medicine hisseleri nereden al\u0131n\u0131r?","answer":"Editas Medicine hisseleri NASDAQ borsas\u0131nda \"EDIT\" sembol\u00fc ile i\u015flem g\u00f6r\u00fcr. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"Editas Medicine hissesi almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r. Baz\u0131 platformlar par\u00e7al\u0131 hisse al\u0131m\u0131na izin vererek d\u00fc\u015f\u00fck miktarlarla yat\u0131r\u0131m yapman\u0131za olanak tan\u0131r."},{"question":"Editas Medicine hissesi almak riskli midir?","answer":"Evet, biyoteknoloji hisseleri genellikle y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131 olarak fiyatlar\u0131 b\u00fcy\u00fck dalgalanmalar g\u00f6sterebilir."},{"question":"Editas Medicine hissesi i\u00e7in uzun vadeli beklentiler nelerdir?","answer":"Uzmanlar, 2025-2030 aras\u0131nda \u015firketin \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip oldu\u011funu ve gen d\u00fczenleme alan\u0131nda \u00f6nc\u00fc konumunu g\u00fc\u00e7lendirece\u011fini \u00f6ng\u00f6rmektedir."},{"question":"Editas Medicine hissesi al\u0131rken nelere dikkat etmeliyim?","answer":"Piyasa haberlerini takip etmek, kazan\u00e7 raporlar\u0131n\u0131 incelemek, stop-loss kullanmak ve portf\u00f6y\u00fcn\u00fczde spek\u00fclatif bir pay ay\u0131rmak \u00f6nemlidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T15:11:45+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T15:11:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\",\"name\":\"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-20T15:11:45+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/","og_locale":"tr_TR","og_type":"article","og_title":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T15:11:45+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T15:11:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/","name":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-20T15:11:45+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-editas-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine, Inc. (EDIT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Editas Medicine, Inc. (EDIT) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":341539,"slug":"how-to-buy-editas-medicine","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Editas Medicine, Inc. (EDIT) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Editas Medicine, Inc. (EDIT)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-editas-medicine\/"},"pt_AA":{"locale":"pt_AA","id":341533,"slug":"how-to-buy-editas-medicine","post_title":"Como comprar a\u00e7\u00f5es da Editas Medicine, Inc. (EDIT) - Investimento em a\u00e7\u00f5es da Editas Medicine, Inc. (EDIT)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-editas-medicine\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=341537"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341537\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=341537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=341537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=341537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}